Enhanced Ocular Delivery of Cell Permeant Therapeutics for Retinal Edema Treatment

The present disclosure relates to novel compositions and methods for the enhanced ocular delivery of cell permeant therapeutics for the treatment of retinal edema, overcoming limitations of existing treatments by providing sustained release formulations, targeted delivery, and improved bioavailability.

Retinal edema is a prevalent condition characterized by fluid accumulation in the retina, often leading to vision loss. Current treatments, such as those described in the original patent, have limitations, including short duration of action, inadequate penetration, and systemic toxicity. The present inventive concept addresses these limitations by introducing novel formulations, delivery methods, and bioavailability enhancers.

The new inventive concept comprises a system for treating retinal edema, featuring a therapeutic composition containing a cell-penetrating peptide conjugate administered to the eye in a sustained release formulation. This allows for prolonged treatment duration, reducing the need for frequent administrations. Additionally, the conjugate may be combined with a permeation enhancer to increase transport across the blood-retina barrier, further enhancing bioavailability. The inventive concept also encompasses methods for reducing inflammation in the retina by administering a caspase-9 inhibitor conjugated to a cell-penetrating peptide, and compositions for treating diabetic macular edema using an XIAP-MTS conjugate.

The new claims introduce novel and non-obvious improvements over the original patent, including sustained release formulations, targeted delivery, and bioavailability enhancers. These innovations provide a significant advancement in the treatment of retinal edema, overcoming the limitations of existing therapies.

Alternative embodiments of the inventive concept may include varying the type and concentration of cell-penetrating peptides, conjugate structures, and delivery formulations. Additionally, the inventive concept could be adapted for use in treating other ocular conditions, such as age-related macular degeneration or uveitis.

The enhanced ocular delivery system for retinal edema treatment has significant commercial potential in the ophthalmology market, with potential applications in treating various retinal diseases and disorders. The targeted delivery and improved bioavailability of the therapeutic composition may lead to improved treatment outcomes, reduced healthcare costs, and enhanced patient quality of life.